ZF Bashshur, AR Schakal, GM El-Mollayess… - Retina, 2011 - journals.lww.com Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. ... Skip Navigation Links Home > Current ... Cited by 1 - Related articles - All 3 versions
D Shima, P Calias… - US Patent 20,110,200,593, 2011 - freepatentsonline.com 16. A method for treating an ocular neovascular disorder, comprising administering to a mammal in need thereof: (a) a PDGF antagonist, wherein the PDGF antagonist is a pegylated aptamer having the sequence of SEQ ID NO: 23; and (b) a VEGF antagonist, wherein the VEGF ... Cached
C Campa, R Hagan, JN Sahni, MC Brown… - … Ophthalmology & Visual …, 2011 - ARVO Methods. This was an observational, longitudinal, prospective study. Treatment-naive patients with nAMD who met the inclusion and exclusion criteria underwent a course of monthly injections of ranibizumab over 3 months. At baseline and month 3, each subject was evaluated with ... Related articles - All 3 versions
AJ Gess, AE Fung… - Seminars in …, 2011 - informahealthcare.com Fluorescein angiography gained in popularity as a useful imaging modality for AMD in the 1970s and it remains the gold standard today. Fluorescein sodium (aka resorcinolphathalein sodium) is a yellow, synthetic salt dye that is most commonly used to evaluate the flow ... Related articles - All 2 versions
JJ Tseng, SK Vance, KE Della Torre… - Journal of …, 2011 - journals.lww.com Wolters Kluwer Health may email you for journal alerts and information, but is committed to maintaining your privacy and will not share your personal information without your express consent. For more information, please refer to our Privacy Policy. ... Skip Navigation Links Home > ... Cited by 2 - Related articles - All 4 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
